Who Paid My Doc
David Sipala
Podiatrist, Foot & Ankle Surgery Brighton, MA Doctor of Podiatric Medicine
NPI 1821351263 CMS profile 219330
736 Cambridge St, Brighton, MA 02135
General payments
$93,667
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, David Sipala of Brighton, MA is reported in the CMS Open Payments database as having received $93,667 across 342 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $11,198 | 47 | |
| 2024 | General | $42,017 | 70 | |
| 2023 | General | $27,584 | 63 | |
| 2022 | General | $1,839 | 21 | |
| 2021 | General | $5,125 | 51 | |
| 2020 | General | $1,093 | 29 | |
| 2019 | General | $4,811 | 61 |
Beside peers
- David Sipala
- Podiatrist, Foot & Ankle Surgery median
- Middle half of Podiatrist, Foot & Ankle Surgery
- National median
In program year 2025, general payments to David Sipala were reported at $11,198. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.
Show as a table
| Year | David Sipala | Podiatrist, Foot & Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,811 | $389 | $118–$1,406 | $163 |
| 2020 | $1,093 | $191 | $62–$691 | $114 |
| 2021 | $5,125 | $329 | $104–$1,341 | $132 |
| 2022 | $1,839 | $419 | $125–$1,611 | $149 |
| 2023 | $27,584 | $377 | $128–$1,164 | $160 |
| 2024 | $42,017 | $394 | $134–$1,168 | $164 |
| 2025 | $11,198 | $424 | $139–$1,306 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
226
Drug cost
$7,373
Branded share of claims
31.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Santyl Collagenase Clostridium Hist. | Brand | 16 | $6,513 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 40 | $181 | |
| Meloxicam | Generic | 60 | $125 | |
| Prednisone | Generic | 24 | $123 | |
| Hydroxyzine Pamoate | Generic | 28 | $106 | |
| Tramadol Hcl | Generic | 16 | $104 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 15 | $95 | |
| Cephalexin | Generic | 13 | $68 | |
| Hydromorphone Hcl | Generic | 14 | $59 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 58 billing codesPaid by Medicare
$77,474
Medicare patients
265
Services billed
2,275
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 64% | |
| Diabetes | 31% | |
| Chronic kidney disease | 29% | |
| Depression | 28% | |
| Ischemic heart disease | 22% | |
| Osteoporosis | 22% | |
| Cancer | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 56 | 350 | $280 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 56 | 870 | $77 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
342 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Foot & Ankle Surgery in Massachusetts
Harry Schneider
Podiatrist, Foot & Ankle Surgery · Cambridge, MA
Philip Basile
Podiatrist, Foot & Ankle Surgery · Cambridge, MA
Michael Sganga
Podiatrist, Foot & Ankle Surgery · Natick, MA
Joseph Fleck
Podiatrist, Foot & Ankle Surgery · North Chelmsford, MA
Michael Skonieczny
Podiatrist, Foot & Ankle Surgery · Plymouth, MA
Richard Baker
Podiatrist, Foot & Ankle Surgery · Hyannis, MA
Related records
Podiatrist, Foot & Ankle Surgery in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Foot & Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.